Vanda Pharmaceuticals Inc. (VNDA)

Over the past six months, Vanda Pharmaceuticals' stock price has seen a significant increase. The FDA approval of NEREUS for motion sickness led to a surge in VNDA shares, and the FDA approved BYSANTI in February 2026. Vanda reported Q4 2025 earnings, which were followed by a decline in share price. The FDA accepted Vanda's Biologics License Application (BLA) for Imsidolimab in Generalized Pustular Psoriasis. Vanda reported Q1 2026 financial results, with total net product sales increasing year-over-year, and raised its full-year 2026 revenue guidance, but VNDA shares declined the day after. Vanda announced the U.S. commercial availability of NEREUS through a direct-to-consumer platform.

Demand seasonality for Vanda Pharmaceuticals' products appears to have some influences, particularly related to insurance shifts and inventory management. Patient demand for PONVORY has been steady despite seasonal insurance shifts. HETLIOZ sales can fluctuate due to inventory stocking patterns, and the company has warned that sales may decline significantly in the future due to persistent generic competition.

Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing therapies for high unmet medical needs, operating in the Healthcare sector, specifically in the Biotechnology & Drugs industry. The company focuses on neurologic, psychiatric, dermatologic, sleep, and inflammatory conditions. Its commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances associated with Smith-Magenis Syndrome. Fanapt is used for the treatment of schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. PONVORY is used for relapsing forms of multiple sclerosis and is in clinical development for psoriasis and ulcerative colitis. NEREUS is approved for the prevention of vomiting induced by motion in adults and is in clinical development for gastroparesis and for the prevention of nausea and vomiting induced by GLP-1 receptor agonists. Bysanti is approved for bipolar I disorder and schizophrenia, and is in a Phase III clinical study for adjunctive treatment of major depressive disorder. Vanda also has an active pipeline of investigational therapies, including Imsidolimab, VTR-297, and VQW-765.

Vanda Pharmaceuticals is a global biopharmaceutical company with the majority of its revenue derived from product sales predominantly in the United States, with additional sales in Israel, Europe, and Canada. The company's corporate headquarters are located in Washington, D.C., and it also has offices in the United Kingdom and Germany.

Vanda Pharmaceuticals' brand reputation in the past year has been positively influenced by its advancements in product development and commercialization. The FDA approvals of NEREUS and BYSANTI have enhanced the company's standing as an innovator. The launch of NEREUS through a direct-to-consumer platform also demonstrates a strategic and patient-centric approach. The decline in HETLIOZ sales due to generic competition presents a business challenge, but has not been explicitly cited as a negative impact on the company's overall brand reputation.

Vanda Pharmaceuticals Inc. has a diverse ownership structure, with institutional investors holding a significant portion of the company's stock. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Renaissance Technologies Llc. Institutional ownership accounts for approximately 65.86% of the company, while individuals hold about 8.71%.